The 2018 breakthrough of the rare disease drug Onpattro, and further advances in RNAi last year, has now set the stage for a trio of biotechs: Alnylam Pharmaceuticals, developer of Onpattro, Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals.
As the just-wrapped J.P. Morgan Healthcare Conference sets the tone for 2020, all three look to build on their field's momentum, which has sparked resurgent interest from large pharmaceutical companies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,